Ivan Spasojevic

Journal Article Nat Commun · April 2, 2025 Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) targeting HER2, exhibiting significant clinical efficacy in breast cancer (BC) with varying HER2 expression, including HER2-low and HER2-ultralow. However, the precise mechanism underlying ... Full text Link to item Cite

Design of an equilibrative nucleoside transporter subtype 1 inhibitor for pain relief.

Journal Article Nat Commun · December 30, 2024 The current opioid crisis urgently calls for developing non-addictive pain medications. Progress has been slow, highlighting the need to uncover targets with unique mechanisms of action. Extracellular adenosine alleviates pain by activating the adenosine A ... Full text Link to item Cite

Safety Evaluations of Rapamycin Perfluorocarbon Nanoparticles in Ovarian Tumor-Bearing Mice.

Journal Article Nanomaterials (Basel) · October 31, 2024 Nanomedicine holds great potential for revolutionizing medical treatment. Ongoing research and advancements in nanotechnology are continuously expanding the possibilities, promising significant advancements in healthcare. To fully harness the potential of ... Full text Link to item Cite

View All Publications

Education, Training & Certifications

Duke University · 1999 Ph.D.

Ivan Spasojevic

Current Appointments & Affiliations

Recent Publications

Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd).

Design of an equilibrative nucleoside transporter subtype 1 inhibitor for pain relief.

Safety Evaluations of Rapamycin Perfluorocarbon Nanoparticles in Ovarian Tumor-Bearing Mice.

Recent Grants

Boston Children's/UCLA/Duke Next Generation Regeneration for Osteoarthritis (BUD NextGenRegen for OA)

Inhibiting Rev1-mediated DNA translesion synthesis for cancer therapy

Developing equilibrative nucleoside transporter inhibitors as non-opioid pain therapeutics

Education, Training & Certifications